DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will deliver an oral presentation at the Hep-DART 2025 meeting, to take place December 7–11, 2025, at the Hilton Hawaiian Village in Honolulu, Hawaii. The presentation will feature data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV. "We ar. ...

Core Viewpoint - Precision BioSciences, Inc. has announced an underwritten offering to sell 10,815,000 shares of its common stock along with warrants to purchase up to 5,407,500 additional shares at a combined price of $6.14 [1] Company Summary - The company is a clinical stage gene editing firm utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies targeting diseases with high unmet needs [1] - The offering includes both common stock and accompanying warrants, indicating a strategy to raise capital for further development [1]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] Group 1 - The company announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 [1] - The presentation will include data from the ongoing ELIMINATE-B Phase 1 study [1] - The study evaluates PBGENE-HBV, which is described as a first-in-class in vivo gene editing therapy [1]

Core Insights - Precision BioSciences, Inc. reported financial results for Q3 2025, highlighting significant advancements in its gene editing pipeline and promising Phase 1 safety and efficacy data for its product PBG [1] Financial Performance - The company announced its financial results for the third quarter ended September 30, 2025, indicating progress in its operations [1] Business Update - Precision BioSciences emphasized strong progress in its gene editing pipeline throughout the third quarter, showcasing the effectiveness of its proprietary ARCUS® platform [1]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] - The company will publish its financial results for the third quarter of 2025 and provide a business update on November 3, 2025 [1] Company Overview - Precision BioSciences utilizes its proprietary ARCUS® platform for gene editing [1] - The company is dedicated to improving life through innovative gene editing solutions [1]

Core Insights - Precision BioSciences, Inc. has been selected for a late-breaking oral presentation at the Liver Meeting® 2025, highlighting its innovative gene editing capabilities [1] Company Summary - The company specializes in gene editing using its proprietary ARCUS® platform, focusing on developing in vivo gene editing therapies for diseases with high unmet medical needs [1] - The presentation will showcase new data from the PBGENE-HBV program, specifically from the first two cohorts of the Phase 1 ELIMINATE-B Trial [1]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] - The company announced the publication of a peer-reviewed manuscript in the journal Nucleic Acids Research, showcasing the efficiency of its proprietary ARCUS® platform [1] - The publication highlights the capability of the engineered homing endonuclease ARCUS for high-efficiency homology-directed insertion into the genome [1] Company Summary - Precision BioSciences utilizes its novel ARCUS® platform for gene editing, targeting diseases that currently lack effective treatments [1] - The recent publication serves to validate the technology and its potential applications in gene therapy [1] - The focus on in vivo therapies indicates a strategic direction towards addressing complex genetic disorders [1]

Core Insights - Precision BioSciences, Inc. has activated its first U.S. clinical trial site for PBGENE-HBV as part of the ELIMINATE-B Phase 1 clinical trial [1] - The clinical trial site is located at Massachusetts General Hospital in Boston, Massachusetts, and is now actively recruiting patients [1] Company Overview - Precision BioSciences is a clinical stage gene editing company that utilizes its proprietary ARCUS® platform [1] - The company focuses on developing in vivo gene editing therapies for diseases with high unmet medical needs [1]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] - The company will present late-breaking preclinical data for its product PBGENE-DMD at the 30th Annual International Congress of the World Muscle Society in Vienna, Austria, from October 7-12, 2025 [1]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] - The company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV targeting chronic Hepatitis B patients [1] - The presentation took place at the International Coalition to Eliminate HBV (ICE-HBV) "HBV Cure Symposium" in Berlin [1]